131 related articles for article (PubMed ID: 26972866)
1. Application of nano-surface and molecular-orientation limited proteolysis to LC-MS bioanalysis of cetuximab.
Iwamoto N; Takanashi M; Umino Y; Aoki C; Hamada A; Shimada T
Bioanalysis; 2016 May; 8(10):1009-20. PubMed ID: 26972866
[TBL] [Abstract][Full Text] [Related]
2. Validated LC/MS Bioanalysis of Rituximab CDR Peptides Using Nano-surface and Molecular-Orientation Limited (nSMOL) Proteolysis.
Iwamoto N; Takanashi M; Hamada A; Shimada T
Biol Pharm Bull; 2016 Jul; 39(7):1187-94. PubMed ID: 27150271
[TBL] [Abstract][Full Text] [Related]
3. Fully validated LCMS bioanalysis of Bevacizumab in human plasma using nano-surface and molecular-orientation limited (nSMOL) proteolysis.
Iwamoto N; Umino Y; Aoki C; Yamane N; Hamada A; Shimada T
Drug Metab Pharmacokinet; 2016 Feb; 31(1):46-50. PubMed ID: 26830079
[TBL] [Abstract][Full Text] [Related]
4. Validated LC-MS/MS analysis of immune checkpoint inhibitor Nivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis.
Iwamoto N; Shimada T; Terakado H; Hamada A
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jun; 1023-1024():9-16. PubMed ID: 27155936
[TBL] [Abstract][Full Text] [Related]
5. Application of nSMOL coupled with LC-MS bioanalysis for monitoring the Fc-fusion biopharmaceuticals Etanercept and Abatacept in human serum.
Iwamoto N; Yokoyama K; Takanashi M; Yonezawa A; Matsubara K; Shimada T
Pharmacol Res Perspect; 2018 Jul; 6(4):e00422. PubMed ID: 30062014
[TBL] [Abstract][Full Text] [Related]
6. Acceleration of nano-surface and molecular-orientation limited (nSMOL) proteolysis with acidified reduction pretreatment for quantification of Tocilizumab.
Iwamoto N; Yonezawa A; Matsubara K; Shimada T
J Pharm Biomed Anal; 2019 Feb; 164():467-474. PubMed ID: 30447535
[TBL] [Abstract][Full Text] [Related]
7. Regulated LC-MS/MS bioanalysis technology for therapeutic antibodies and Fc-fusion proteins using structure-indicated approach.
Iwamoto N; Shimada T
Drug Metab Pharmacokinet; 2019 Feb; 34(1):19-24. PubMed ID: 30392772
[TBL] [Abstract][Full Text] [Related]
8. LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients.
Iwamoto N; Shimomura A; Tamura K; Hamada A; Shimada T
J Pharm Biomed Anal; 2017 Oct; 145():33-39. PubMed ID: 28648785
[TBL] [Abstract][Full Text] [Related]
9. Multiplexed monitoring of therapeutic antibodies for inflammatory diseases using Fab-selective proteolysis nSMOL coupled with LC-MS.
Iwamoto N; Takanashi M; Yokoyama K; Yonezawa A; Denda M; Hashimoto M; Tanaka M; Ito H; Matsuura M; Yamamoto S; Honzawa Y; Matsubara K; Shimada T
J Immunol Methods; 2019 Sep; 472():44-54. PubMed ID: 31201793
[TBL] [Abstract][Full Text] [Related]
10. Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum.
Iwamoto N; Yokoyama K; Takanashi M; Yonezawa A; Matsubara K; Shimada T
Curr Pharm Biotechnol; 2018; 19(6):495-505. PubMed ID: 29968534
[TBL] [Abstract][Full Text] [Related]
11. Antibody drug quantitation in coexistence with anti-drug antibodies on nSMOL bioanalysis.
Iwamoto N; Hamada A; Shimada T
Anal Biochem; 2018 Jan; 540-541():30-37. PubMed ID: 29128290
[TBL] [Abstract][Full Text] [Related]
12. Structure-Indicated LC-MS/MS Bioanalysis of Therapeutic Antibodies.
Iwamoto N; Shimada T
Methods Mol Biol; 2022; 2313():187-205. PubMed ID: 34478139
[TBL] [Abstract][Full Text] [Related]
13. Selective detection of complementarity-determining regions of monoclonal antibody by limiting protease access to the substrate: nano-surface and molecular-orientation limited proteolysis.
Iwamoto N; Shimada T; Umino Y; Aoki C; Aoki Y; Sato TA; Hamada A; Nakagama H
Analyst; 2014 Feb; 139(3):576-80. PubMed ID: 24326404
[TBL] [Abstract][Full Text] [Related]
14. Simple and rapid LC-MS/MS method for the absolute determination of cetuximab in human serum using an immobilized trypsin.
Shibata K; Naito T; Okamura J; Hosokawa S; Mineta H; Kawakami J
J Pharm Biomed Anal; 2017 Nov; 146():266-272. PubMed ID: 28888713
[TBL] [Abstract][Full Text] [Related]
15. Liquid chromatography-mass spectrometry for the quantitative bioanalysis of anticancer drugs.
Stokvis E; Rosing H; Beijnen JH
Mass Spectrom Rev; 2005; 24(6):887-917. PubMed ID: 15599948
[TBL] [Abstract][Full Text] [Related]
16. What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?
Vialaret J; Broutin S; Pugnier C; Santelé S; Jaffuel A; Barnes A; Tiers L; Pelletier L; Lehmann S; Paci A; Hirtz C
Bioanalysis; 2018 May; 10(10):723-735. PubMed ID: 29771137
[TBL] [Abstract][Full Text] [Related]
17. A universal surrogate peptide to enable LC-MS/MS bioanalysis of a diversity of human monoclonal antibody and human Fc-fusion protein drug candidates in pre-clinical animal studies.
Furlong MT; Ouyang Z; Wu S; Tamura J; Olah T; Tymiak A; Jemal M
Biomed Chromatogr; 2012 Aug; 26(8):1024-32. PubMed ID: 22623136
[TBL] [Abstract][Full Text] [Related]
18. LC-FAIMS-MS/MS for quantification of a peptide in plasma and evaluation of FAIMS global selectivity from plasma components.
Xia YQ; Wu ST; Jemal M
Anal Chem; 2008 Sep; 80(18):7137-43. PubMed ID: 18652493
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Bevacizumab Quantification Results in Plasma of Non-small Cell Lung Cancer Patients Using Bioanalytical Techniques Between LC-MS/MS, ELISA, and Microfluidic-based Immunoassay.
Iwamoto N; Takanashi M; Shimada T; Sasaki J; Hamada A
AAPS J; 2019 Aug; 21(6):101. PubMed ID: 31432293
[TBL] [Abstract][Full Text] [Related]
20. Determination of plasma concentration of Belimumab by LC-MS/MS: Method development, validation, and clinical application.
Marin C; Noé G; Schlemmer D; Beaulieu Q; Robidou P; Mansour B; Hirtz C; Vialaret J; Antignac M; Moyon Q; Benameur N; Amoura Z; Zahr N
J Pharm Biomed Anal; 2023 Nov; 236():115730. PubMed ID: 37734255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
